Catalog No.
KAH02252
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
15.625-1,000 ng/ml
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Alternative Names
BMS-936558,MDX-1106,ONO-4538, CAS: 946414-94-4
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours., PMID:39663448
The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer., PMID:39103762
Immunotherapies for advanced hepatocellular carcinoma., PMID:37025485
Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy., PMID:36857433
The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model., PMID:36077380
Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays., PMID:34608545
Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer., PMID:34253638
Advances in immunotherapy for hepatocellular carcinoma., PMID:33850328
COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer., PMID:32540268
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit., PMID:31402780
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma., PMID:29959458
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors., PMID:27557786
Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential., PMID:26098609